Organogenesis Share Price (NASDAQ: ORGO)

$5.16

▲

0.04

(0.78%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Organogenesis Stock chart to analyse performance

Organogenesis stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$5.06
Today's High:$5.16
$5.16
1.94%
Downside
Day's Volatility :1.94%
Upside
0.0%
52 Weeks Low:$2.46
52 Weeks High:$6.71
$5.16
52.42%
Downside
52 Weeks Volatility :63.41%
Upside
23.1%

Organogenesis Stock Returns

Period	Organogenesis Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	93.98%	3.6%	0.0%
6 Months	-4.62%	-7.7%	0.0%
1 Year	89.01%	-12.6%	0.0%
3 Years	40.6%	9.5%	-4.7%

Organogenesis Holdings Inc Key Stats

Check Organogenesis key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$5.12
Open	$5.12
Today's High	$5.16
Today's Low	$5.06
Market Capitalization	$649.5M
Today's Volume	$314.2K
52 Week High	$6.71
52 Week Low	$2.455
Revenue TTM	$429.5M
EBITDA	$3.2M
Earnings Per Share (EPS)	$-0.14
Profit Margin	-1.92%
Quarterly Earnings Growth YOY	3.5%
Return On Equity TTM	-2.63%

Stock Returns calculator for Organogenesis Stock including INR - Dollar returns

The Organogenesis stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Organogenesis investment value today

Current value as on today

₹1,94,295

Returns

₹94,295

(+94.3%)

Returns from Organogenesis Stock

₹89,011 (+89.01%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Organogenesis Stock

-41%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Organogenesis Stock from India on INDmoney has decreased by -41% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Organogenesis Holdings Inc

Name
Holdings %
Name
Holdings %
Soleus Capital Management, L.P.
9.73%
Morgan Stanley - Brokerage Accounts
9.55%
First Light Asset Management, LLC
5.34%
Vanguard Group Inc
4.10%
BlackRock Inc
4.06%
Dimensional Fund Advisors, Inc.
2.45%

Analyst Recommendation on Organogenesis Stock

Rating

Trend

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Organogenesis(by analysts ranked 0 to 5 stars)

Organogenesis Share Price Target

What analysts predicted

Upside of 55.04%

Target:

$8.00

Current:

$5.16

Organogenesis share price target is $8.00, a slight Upside of 55.04% compared to current price of $5.16 as per analysts' prediction.

Organogenesis Stock Insights

Price Movement
In the last 3 months, ORGO stock has moved up by 88.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 86.69M → 101.00M (in $), with an average increase of 14.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -21.59M → -9.39M (in $), with an average increase of 129.9% per quarter

Organogenesis Holdings Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$261.0M	↑ 34.91%
Net Income	$-40.5M	↓ 37.6%
Net Profit Margin	-15.5%	↑ 18.01%

	FY20	Y/Y Change
Revenue	$338.3M	↑ 29.63%
Net Income	$17.2M	↓ 142.6%
Net Profit Margin	5.09%	↑ 20.59%

	FY21	Y/Y Change
Revenue	$468.1M	↑ 38.36%
Net Income	$94.2M	↑ 446.61%
Net Profit Margin	20.13%	↑ 15.04%

	FY22	Y/Y Change
Revenue	$450.9M	↓ 3.67%
Net Income	$15.5M	↓ 83.51%
Net Profit Margin	3.44%	↓ 16.69%

	FY23	Y/Y Change
Revenue	$433.1M	↓ 3.94%
Net Income	$4.9M	↓ 68.16%
Net Profit Margin	1.14%	↓ 2.3%

	FY24	Y/Y Change
Revenue	$482.0M	↑ 11.29%
Net Income	$861.0K	↓ 82.59%
Net Profit Margin	0.18%	↓ 0.96%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$110.0M	↑ 10.36%
Net Income	$-2.1M	↑ 269.72%
Net Profit Margin	-1.91%	↓ 1.34%

	Q2 FY24	Q/Q Change
Revenue	$130.2M	↑ 18.42%
Net Income	$-17.0M	↑ 711.57%
Net Profit Margin	-13.09%	↓ 11.18%

	Q3 FY24	Q/Q Change
Revenue	$115.2M	↓ 11.56%
Net Income	$12.3M	↓ 172.35%
Net Profit Margin	10.71%	↑ 23.8%

	Q4 FY24	Q/Q Change
Revenue	$126.7M	↑ 9.97%
Net Income	$7.7M	↓ 37.77%
Net Profit Margin	6.06%	↓ 4.65%

	Q1 FY25	Q/Q Change
Revenue	$86.7M	↓ 31.55%
Net Income	$-21.6M	↓ 381.39%
Net Profit Margin	-24.91%	↓ 30.97%

	Q2 FY25	Q/Q Change
Revenue	$101.0M	↑ 16.51%
Net Income	$-9.4M	↓ 56.5%
Net Profit Margin	-9.3%	↑ 15.61%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$185.0M	↑ 48.45%

	FY20	Y/Y Change
Profit	$251.0M	↑ 35.64%

	FY21	Y/Y Change
Profit	$353.9M	↑ 40.99%

	FY22	Y/Y Change
Profit	$345.9M	↓ 2.26%

	FY23	Y/Y Change
Profit	$326.7M	↓ 5.56%

	FY24	Y/Y Change
Profit	$366.3M	↑ 12.14%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$77.6M	↑ 14.51%

	Q2 FY24	Q/Q Change
Profit	$104.7M	↑ 34.89%

	Q3 FY24	Q/Q Change
Profit	$88.4M	↓ 15.58%

	Q4 FY24	Q/Q Change
Profit	$95.6M	↑ 8.17%

	Q1 FY25	Q/Q Change
Profit	$63.0M	↓ 34.14%

	Q2 FY25	Q/Q Change
Profit	$66.7M	↑ 5.96%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-33.5M	↓ 44.8%
Investing Cash Flow	$-6.2M	↑ 235.88%
Financing Cash Flow	$78.7M	↓ 3.57%

	FY20	Y/Y Change
Operating Cash Flow	$6.8M	↓ 120.28%
Investing Cash Flow	$-24.8M	↑ 298.35%
Financing Cash Flow	$42.5M	↓ 46.06%

	FY21	Y/Y Change
Operating Cash Flow	$62.0M	↑ 811.31%
Investing Cash Flow	$-31.2M	↑ 25.72%
Financing Cash Flow	$-1.0M	↓ 102.44%

	FY22	Y/Y Change
Operating Cash Flow	$24.9M	↓ 59.89%
Investing Cash Flow	$-33.9M	↑ 8.58%
Financing Cash Flow	$-2.2M	↑ 112.26%

	FY23	Y/Y Change
Operating Cash Flow	$30.9M	↑ 24.37%
Investing Cash Flow	$-24.4M	↓ 28.13%
Financing Cash Flow	$-5.5M	↑ 150.34%

	FY24	Y/Y Change
Operating Cash Flow	$14.2M	↓ 54.04%
Investing Cash Flow	$-10.0M	↓ 58.82%
Financing Cash Flow	$27.6M	↓ 602.03%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-10.2M	↓ 195.75%
Investing Cash Flow	$-2.2M	↓ 33.15%
Financing Cash Flow	$-2.6M	↑ 46.76%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$4.7M	↓ 146.62%
Investing Cash Flow	$-1.9M	↓ 15.39%
Financing Cash Flow	$-1.7M	↓ 33.78%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$8.7M	↑ 83.52%
Investing Cash Flow	$-2.6M	↑ 36.65%
Financing Cash Flow	$-1.7M	↓ 2.9%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$10.9M	↑ 25.78%
Investing Cash Flow	$-3.4M	↑ 30.83%
Financing Cash Flow	$33.6M	↓ 2106.5%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-19.9M	↓ 282.27%
Investing Cash Flow	$-3.6M	↑ 7.88%
Financing Cash Flow	$-2.1M	↓ 106.11%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-32.9M	↑ 64.9%
Investing Cash Flow	$-3.6M	↑ 0.33%
Financing Cash Flow	$-288.0K	↓ 85.99%

Organogenesis Technicals Summary

Sell

Neutral

Buy

Organogenesis is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Organogenesis Holdings Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Organogenesis Holdings Inc	14.41%	-4.62%	89.01%	40.6%	-71.57%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Organogenesis Holdings Inc	63.75	NA	NA	0.08	-0.03	-0.02	NA	1.84
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Organogenesis Holdings Inc	Buy	$649.5M	-71.57%	63.75	-1.92%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Organization	Organogenesis
Employees	869
CEO	Mr. Gary S. Gillheeney Sr.
Industry	Finance

Key Management of Organogenesis Holdings Inc

Name	Title
Mr. Gary S. Gillheeney Sr.	President, CEO, Chair of the Board
Mr. David C. Francisco	Chief Financial Officer
Mr. Patrick Bilbo	Chief Operating Officer
Ms. Lori H. Freedman B.A., Esq., J.D.	Chief Administrative & Legal Officer
Mr. Brian Grow	Chief Commercial Officer
Mr. William R. Kolb CPA	Secretary
Mr. Robert Cavorsi	Vice President of Strategy

Important FAQs about investing in ORGO Stock from India :

What is Organogenesis share price today?

Organogenesis share price today is $5.16 as on August 30, 2025 at 1:29 am IST at the close of the market. Organogenesis share today touched a day high of $5.16 and a low of $5.06.

What is the 52 week high and 52 week low for Organogenesis share?

Organogenesis share touched a 52 week high of $6.71 and a 52 week low of $2.46. Organogenesis stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $5.16, lower by 23.1% versus the 52 week high.

How to invest in Organogenesis Stock (ORGO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Organogenesis on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Organogenesis Shares that will get you 0.2907 shares as per Organogenesis share price of $5.16 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Organogenesis Stock (ORGO) from India?

Indian investors can start investing in Organogenesis (ORGO) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Organogenesis stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Organogenesis share’s latest price of $5.16 as on August 30, 2025 at 1:29 am IST, you will get 1.9380 shares of Organogenesis. Learn more about fractional shares .

What are the returns that Organogenesis has given to Indian investors in the last 5 years?

Organogenesis stock has given -71.57% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?